OOIR: Observatory of International Research

Papers

(The H4-Index of Drug Discovery Today is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Contents page 2	233
Contents page	215
Multiple strategies for the treatment of invasive breast carcinoma: A comprehensive prospective	190
Adjunctive therapy for multidrug-resistant bacterial infections: Type III secretion system and efflux inhibitors	190
Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites	165
Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity	150
Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	135
Double-edged sword: Therapeutic efficacy versus toxicity evaluations of doped titanium implants	126
The recent progress of deep-learning-based in silico prediction of drug combination	124
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies	120
CIPDB: A biological structure databank for studying cation and π interactions	113
Recent development in the design of small ‘drug-like’ and nanoscale glycomimetics against Escherichia coli infections	112
General aspects of powder rheology applied to pharmaceutical formulations	108
Tubulin targeting agents and their implications in non-cancer disease management	108
The potential value of 5-androstenediol in countering acute radiation syndrome	107
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds	99
Mitochondrial dysfunction: A potential target for Alzheimer’s disease intervention and treatment	96
Models and approaches to comprehend and address glial inflammation following spinal cord injury	93
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy	90
The global status of bioequivalence trials: a comprehensive clinical trial landscape analysis based on the Trialtrove database	87
Computational modeling approaches and regulatory pathways for drug combinations	86
Gastroretentive drug delivery systems: A holy grail in oral delivery	84
From promise to progress: the dynamic landscape of glioblastoma immunotherapy	83
Antibody–drug conjugates: What drives their progress?	80
Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases	79

A global bibliometric and visualized analysis of bacteria-mediated cancer therapy	77
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	77
Repurposing of parenterally administered active substances used to treat pain both systemically and locally	77
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five	76
Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders	76
Specificity of pharmacokinetic modeling of nanomedicines	76
Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics	74
Contents page 2	72
Recent advancements in mass spectrometry for higher order structure characterization of protein therapeutics	71
Advancing pharmacogenetics research in Africa: the “Project Africa GRADIENT” initiative	71
Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol’s editorial on biosimilars of follitropin alfa	71
Pathogenic TDP-43 in amyotrophic lateral sclerosis	70
Bridging informatics and medicinal inorganic chemistry: Toward a database of metallodrugs and metallodrug candidates	69
Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease	68
Towards Pharma 4.0 in clinical trials: A future-orientated perspective	67
Molecular approaches for the treatment and prevention of Friedreich's ataxia	67
Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases	64
Investigating miRNA subfamilies: Can they assist in the early diagnosis of acute myocardial infarction?	63
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?	62
MTHFD2: A significant mitochondrial metabolic enzyme and a novel target for anticancer therapy	62
Systematic review and QSPR analysis of chemical penetration through the nail to inform onychomycosis candidate selection	59
MRI assessment of cerebral perfusion in clinical trials	58
The main aspects of non-clinical studies required for obtaining marketing authorisation for small molecules and biologics/biopharmaceuticals in the European Union and the United States	58
Steps toward nebulization in-use studies to understand the stability of new biological entities	58
Caught between a ROCK and a hard place: current challenges in structure-based drug design	55
Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development	55
Recent advances towards overcoming the blood–brain barrier	54
Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases	54
Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio	54
Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein	54
Medicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer	54
Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance	54
Targeted protein degradation: current molecular targets, localization, and strategies	54